Literature DB >> 15572484

Fulminant sepsis after invasive prenatal diagnosis.

Nicolaos Plachouras1, Alexandros Sotiriadis, Nicolaos Dalkalitsis, Emmanuel Kontostolis, Nicolaos Xiropotamos, Evangelos Paraskevaidis.   

Abstract

BACKGROUND: Sepsis is extremely rare after invasive prenatal diagnosis. CASE: A patient, who had undergone amniocentesis at 15 weeks, cordocentesis at 20 weeks, and repeat cordocentesis 24 hours before presentation, was admitted at 21 weeks gestation with vaginal bleeding, rupture of membranes, and intrauterine demise. Although clinical and laboratory findings were unremarkable at presentation, she rapidly developed septic syndrome with disseminated intravascular coagulation and eventually multiple organ failure. The fetus was disintegrated and the uterus had to be removed. She was discharged from the intensive care unit after 34 days. Cultures of the uterine content grew Clostridium perfringens. Review of the literature revealed 10 more cases of sepsis after transabdominal prenatal diagnosis.
CONCLUSION: Sepsis after prenatal diagnosis can be devastating, unless promptly diagnosed and treated.

Entities:  

Mesh:

Year:  2004        PMID: 15572484     DOI: 10.1097/01.AOG.0000141650.01076.98

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  2 in total

1.  The diagnostic performance of the Mass Restricted (MR) score in the identification of microbial invasion of the amniotic cavity or intra-amniotic inflammation is not superior to amniotic fluid interleukin-6.

Authors:  Roberto Romero; Nicholas Kadar; Jezid Miranda; Steven J Korzeniewski; Alyse G Schwartz; Piya Chaemsaithong; Wade Rogers; Eleazar Soto; Francesca Gotsch; Lami Yeo; Sonia S Hassan; Tinnakorn Chaiworapongsa
Journal:  J Matern Fetal Neonatal Med       Date:  2013-12-16

2.  Clostridial abdominal gas gangrene masquerading as a bowel perforation in an advanced-stage ovarian cancer patient.

Authors:  L N Abaid; R H Thomas; H D Epstein; B H Goldstein
Journal:  Infection       Date:  2013-03-15       Impact factor: 3.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.